Admin

Complete pre-determined information indications and usage AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This can be demonstrated by an increase in walking speed [see Clinical Studies (14)]. Dosage and Administration The maximum recommended dose of AMPHRA is 10 mg tablets twice daily, with or without, and should not be exceeded. The dose should be approximately 12 hours apart. If the dose is missed, the patient should not take double or extra doses. No additional benefit was demonstrated at doses greater than 10 mg twice due to adverse effects, daily and adverse reactions and interruptions were more common at higher doses. Tablets should only be used as a whole; do not split, smash, chew or dissolve. AMPYRA is contraindicated in patients with moderate or severe renal insufficiency [see contraindications (4)]. The risk of seizures in patients with mild renal insufficiency (CrCl 51-80 mL / min) is unclear, but AMPYRA plasma exposure in these patients may be close to the 15 mg dose twice daily, which may increase the risk of seizures; Estimated CrCl should be known before starting treatment with AMPYRA [see Warnings and Precautions, Kidney Injury (5.2) and Clinical Pharmacology, Special Population (12.4)]. [For complete "Instructions for Use", please refer to FDA-approved patient information] Dosage Form and Strength AMMYRA is 10 mg in strength and is a thin film coating, white to off-white, biconvex, elliptical, non-notched flat Side, one side of the depression, "A10". Contraindications The use of AMMYRA is prohibited under the following conditions: Moderate or severe renal impairment warnings and precautions in epileptic seizures 5.1 Seizures AMMYRA is contraindicated in patients with a history of epilepsy [see contraindications (4)]. The incidence of seizures increased by 20 mg twice daily in a control clinical study with dalfampridine for 9-14 weeks in patients with MS. A seizure (0.4%) was observed in the placebo group and a dose of 10 mg twice daily (0.25%), no seizures occurred twice at 15 mg twice daily, and 2 seizures were observed twice at 20 mg twice daily (3.5 %). In the open-label extension trial of MS patients, the incidence of seizures (1.7 / 100PY) during 15 mg of dalfampridine twice daily was 4 times higher than that of 10 mg twice daily (0.4 / 100 PY). AMPYRA has not been evaluated in patients with a history of seizures or EEG epileptiform activity because these patients were excluded from clinical trials. The risk of seizures in patients with EEG epileptiform activity is unclear and may be much higher than the risk of seizures observed in the AMMYRA clinical study. For patients with seizures during treatment, AMMYRA should be discontinued and not restarted. 5.2 Renal impairment AMPYRA is eliminated by the kidney as an unaltered drug [see Clinical Pharmacology, Special Population (12.4)]. Because patients with renal insufficiency require less than 10 mg per day and no intensity less than 10 mg, AMMYRA is contraindicated in patients with moderate to severe renal insufficiency [creatinine clearance (CrCl) ≤ 50 mL/min] [see contraindications] Symptoms] (4)]. The risk of seizures in patients with mild renal insufficiency (CrCl 51-80 mL / min) is unclear, but the plasma levels of diaminopiperidine in these patients may be close to twice daily doses of 15 mg, which may be Increased risk of seizures [see Warnings and Precautions, Seizures (5.1)]. If you don't know, you should estimate CrCl before starting treatment with AMPYRA. CrCl can be estimated using the following equation (female multiplied by 0.85): 5.3 Simultaneous treatment with other forms of 4-aminopyridine AMMYRA should not be taken with other forms of 4-aminopyridine (4-AP, pyridinium) because of the active ingredient Are the same. Patients should discontinue treatment with AMPYRA with any product containing 4-aminopyridine prior to initiation to reduce the likelihood of dose-related adverse effects. 5.4 Urinary tract infection compared with placebo (8%), receiving AMMYRA 10 Read more...

English Name: Canasa (Mesalamine Suppositories) Description of the drug: This product is light brown to pink needle crystal, odorless or slightly odor. The color becomes darker in the air. It is slightly soluble in water, very slightly soluble in ethanol, acetone and methanol, and insoluble in chloroform, ether, butanol and propanol. Dissolution in dilute hydrochloric acid and dilute hydroxide base. Indications: For the treatment of ulcerative colitis, Crohn's disease; suppositories for the treatment of ulcerative proctitis, can also be combined with mesalazine tablets. Pharmacological action: Mesalazine acts on intestinal mucosa, inhibits the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediator leukotrienes, thereby significantly reducing the inflammation of the intestinal wall and the connective tissue of the intestinal wall. It is especially effective for the treatment of ulcerative colitis and Crohn's Disease. Mesalazine sustained-release tablets consist of ethylcellulose-coated melpharazine to the granules (0.7-1 mm in diameter), which begins to disintegrate in the stomach, and the microparticles enter the small intestine through the pylorus without gastric emptying and without drugs. A large amount of dumping phenomenon, no blood drug peak concentration, short residual time in the stomach, can be measured in the blood within 20 minutes after taking the mesalazine, in the entire pH-wide intestinal tract, continuous release at a constant rate, in the intestine The reduction in delivery time has minimal effect on the release of mesalamine, and the absorption is relatively unchanged, it is not affected by the intestinal flora. Mesalazine is released evenly and slowly from the duodenum to the colon. About 50% of oral mesalazine is released in the small intestine and 50% is released in the large intestine. The sustained release tablet also prevents mesalazine from being prematurely absorbed in the proximal small intestine, thus ensuring its high bioavailability in the distal small intestine. Due to the uniform release of mesalamine throughout the intestine, it is safe and effective in the treatment of chronic intestinal inflammatory diseases. Mesalazine suppository consists of sustained-release microcapsules, which can directly reach the site of action, release slowly, and have a high local concentration. The shape of the suppository is consistent with the physiological structure, which can effectively treat ulcerative colitis. The in vivo process of mesalazine is routinely taken up by the upper digestive tract after oral administration, rarely reaching the colon, t1/2 for about 1 hour, and protein binding rate of 40%-50%. Therefore, a sustained release dosage form is often prepared to exert a local effect in the colon. Mesalazine is converted to acetamidosalicylic acid after release from the colon. A part of acetylaminosalicylic acid is decomposed by bacteria in the intestine and excreted from the feces. Another part of the label is absorbed by the intestinal mucosa, and about 40% is bound to plasma proteins. Metabolism produces acetylated compounds, about 80% of which bind to plasma proteins and are excreted from the urine, with a t1/2 of 5-10 hours, rarely through the placenta and into the milk. Specifications: Suppository: 0.5g, 1g. Dosage: Dosage Oral: Adult, ulcerative colitis (acute episode): 4 times a day, 1g each time; maintenance treatment, 3 times a day, 0.5g each time. Crohn's disease: 4 times a day, 1g each time. For children over 2 years old, take 20-30mg per kilogram of body weight per day, in divided doses. Suppositories: Adults, 1-2 times a day, 1 suppository each time. Children over the age of two, follow the doctor's advice. Adverse reactions: 1. May cause mild gastrointestinal discomfort, nausea, dry mouth, constipation or diarrhea. 2. Others have dizziness, headache, disorientation; joint pain, spastic myalgia, and elevated levels of aminotransferase and BUN. Note 1. Those who are allergic to salicylic acid drugs and excipients of this product are not allowed to use. 2. Patients with liver and kidney dysfunction should be used with caution. Pregnant and breast-feeding patients should be used with caution. Children under 2 years old should not be used. 3. When this product is taken together with cyanocobalamin tablets (vitamin B12 tablets), it will affect the absorption of cyanocobalamin tablets. 4. Usage Note: Tablets: It is best to swallow the whole granules, or smash it or use water; but never chew or crush. If a dose is missed for any reason, it should be replenished as soon as possible or supplemented with the next dose. If there are multiple doses missed, continue to take the prescription and contact the physician as soon as possible. Suppository: Defecation should be done before use. Suppository should be inserted from the anus with latex fingertips. If the suppository drips within 10 minutes, it needs to be re-plugged into another suppository. For easy insertion, water, Vaseline and other lubricants can be used. wet. If a dose is missed for any reason, it should be continued according to the prescription. If multiple doses are missed, continue to use according to the prescription. Storage: Tablets should be stored at room temperature (15-25 ° C), not after the expiration date; suppositories should be stored at room temperature (15-25 ° C) in the original package, not after the expiration date.

English name: PENTASA Suppositories (Mesalamine, 5-Aminosalicylic acid) Chinese name: mesalazine, 5-aminosalicylic acid suppository traits This product is needle-like crystal or crystalline powder grayish white to pale yellow ash, there is a odorless ~ odor. The product has a slightly sweet taste and is still sour. This product is slightly soluble in water, ethanol (99.5), or very sparingly soluble in methanol, and is almost insoluble in diethyl ether or chloroform. Pharmacological Pharmacology 1. Effects of animal models in the acetic acid-induced ulcerative colitis model and the rat TNBS-induced colitis model, in the former, the effect of inhibiting significant ulcer area from 6.25 mg/kg, the latter being significant at 25.0 mg/kg The inhibitory effect was observed by the enema administration of the failed mesalamine. 2. The action of the free radical (DPPHL) in vitro, hydrogen peroxide scavenging activity, ion scavenging hypochlorous acid lowering effect, lipid peroxidation inhibition (in vitro, in vivo) was observed. Rat neutrophils further inhibit the biosynthesis of leukotriene B4 (LTB4) (in vitro). Therefore, erasing the main mode of action of this drug from inflammatory cells, reactive oxygen species, inhibits progression and inflammation of tissue diseases, and inhibits the biosynthesis of LTB 4, which is thought to prevent infiltration of the tissue. . In addition, as another mode of action, histamine release from mast cell inhibition, biosynthesis inhibition of platelet activating factor (PAF), interleukin-1 beta production inhibition (IL-1β) is part of the inferred possibility (in vitro). Adaptation to the condition Ulcerative colitis (excluding severe) Usage and dosage Ulcerative colitis: Adults 1G a day, inserted into the rectum. Packing specification suppository: 1 gram SP package 50 (10 × 5), 100 (10 × 10)

Chinese name: Pomalidomide capsule English name: Pomalidomide Original research company: Celgene corp Foreign market situation United States: Capsules 1mg, 2mg, 3mg, 4mg (2013.2.08); Celgene corp company; trade name Pomalyst EU: capsule 1mg, 2mg, 3mg, 4mg (2013.8.05); held by Celgene Europe Ltd; trade name Imnovid Japan: capsules 1mg, 2mg, 3mg, 4mg (2015.3.26); held by geneーン (Celgene); The mechanism of action of thallium is a thalidomide analog, which is an antitumor activity. Immunomodulator. In in vitro cytology, pomalidomide inhibits hematopoietic tumor cell proliferation and induces apoptosis. In addition, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergistically induced tumor cell apoptosis in lenalidomide-sensitive and lenalidomide-resistant cell lines with dexamethasone. Enhances T cell- and natural killer (NK) cell-mediated immunity and inhibits monocyte pro-inflammatory cytokine production (eg, TNF-[alpha] and IL-6). Anti-angiogenic activity is shown in mouse tumor models and in vitro umbilical cord models. Indications and usage are indicated by thalidomide analogs, in combination with dexamethasone, for patients with multiple myeloma who receive at least two prior therapies, including lenalidomide and proteasome inhibitors, and Disease progression has been confirmed 60 days after the end of the last treatment in or on. Dosage 4 mg, repeated 28 days per day on the day until 1 to 21 of the disease progression. Please refer to the dose of dexamethasone. Contraindications Pregnancy Warnings and Precautions Hematologic Toxicity: Neutropenia is the most common grade 3/4 adverse event. Monitor patient blood system toxicity, especially neutropenia. Liver: Liver failure including death; monitoring liver function tests once a month. Reports of allergic reactions to angioedema and severe skin reactions. For angioedema, discontinue POMALYST and severe dermatological reactions. Tumor Lysis Syndrome (TLS): TLS monitors patients at risk (ie, those with high tumor burden) and takes appropriate precautions. Adverse reactions The most common adverse reactions (≥30%), including fatigue and weakness, leukopenia, anemia, constipation, nausea, diarrhea, dyspnea, upper respiratory tract infections, back pain and fever. Strong interaction with CYP1A2 inhibitors: Avoid the use of strong CYP1A2 inhibitors unless necessary medical care. Breastfeeding mothers in special populations: Please stop taking drugs or breastfeeding to take into account the importance of the drug, taking into account the mother. Avoid serum PEMALYST in patients with serum creatinine > 3.0 mg / dl.

Common Name: Dobasi Capsules Drug Category: Chemical Drugs Properties: Prescription Drug Related Diseases: Parkinson's Disease, Parkinson's Syndrome. Main Ingredients: This product is a compound preparation with the components of levodopa and benserazide hydrochloride. Indications: For Parkinson's disease, Parkinson's disease. Specifications: 0.125 g (levodopa: 0.1 g, benserazide: 25 mg). Adverse reactions: 1. The more common adverse reactions are nausea, vomiting, orthostatic hypotension, abnormal involuntary movements in the head, face, tongue, upper limbs and upper part of the body, depression, difficulty in urinating. 2. Less common adverse reactions are: hypertension, arrhythmia, hemolytic anemia. Dosage: Oral. 1. 125mg once a week, 2 times a day, after every other week, increase 125mg a day, the general daily dose should not exceed 1g, divided into 3 to 4 times. 2. Maintain a dose of 250 mg once a day, 3 times a day. Contraindications: Severe mental illness, severe arrhythmia, heart failure, glaucoma, peptic ulcer, and history of seizures are contraindicated. Note: 1. Hypertension, arrhythmia, diabetes, bronchial asthma, emphysema, liver and kidney dysfunction, urinary retention should be used with caution. 2. Elderly people with osteoporosis who are treated with this product should slowly return to normal activities to reduce the risk of fracture. 3. During the medication, pay attention to check blood routine, liver and kidney function and electrocardiogram. Pregnancy and lactating women medication: 1. This product can be secreted into milk, it will also reduce milk secretion, animal experiments show that this product can cause visceral and skeletal deformities. 2. Pregnant women and lactating women should be banned. Pediatric Use: Use with caution. Elderly medication: 1. Symptoms of poisoning: Overdose can significantly aggravate the above adverse reactions and can lead to severe arrhythmias. 2. Treatment: Immediately induce vomiting, gastric lavage, take measures to increase excretion, and carry out corresponding symptomatic treatment and supportive therapy according to the condition. Drug interactions: 1. This product combined with non-selective monoamine oxidase inhibitors can cause acute adrenal crisis. 2. This product is combined with papaverine or vitamin B6 to reduce the efficacy of this product. 3. This product is combined with acetylspiramycin, which can significantly reduce the blood concentration of this product, and the efficacy is weakened. 4. This product can be combined with reserpine to inhibit the action of this product and should be avoided. 5. This product is used in combination with antipsychotic drugs. Because the two are antagonistic to each other, they should be avoided. 6. This product is combined with methyldopa to increase the adverse reactions of this product and enhance the antihypertensive effect of methyldopa. Pharmacology and Toxicology: 1. This product is a compound preparation containing levodopa and benserazide. Benserazide is a peripheral decarboxylase inhibitor, which is not easy to enter the center. It only inhibits the conversion of peripheral levodopa to dopamine, which makes the levodox in the circulation. The content of bar is increased by 5-10 times, so the amount of levodopa entering the central center is also increased. Levodopa is converted into dopamine by dopa decarboxylase in the brain to exert pharmacological effects and improve the symptoms of Parkinson's disease. 2. Combination of benserazide and levodopa can reduce the adverse reactions of levodopa peripheral cardiovascular system and reduce the dosage of levodopa. Pharmacokinetics: 1. Absorbed by the small intestine after oral administration. After fasting, levodopa has a peak plasma concentration of 1~2 hours, widely distributed in various tissues in the body, 1% enters the central body and transforms into dopamine to play a role, most of which are metabolized outside the brain to become dopamine, so it works. slow. 2. Half-life (t1/2) is 1~3 hours. Adding peripheral dopa decarboxylase inhibitor can reduce the dosage of levodopa, increase the amount of levodopa into the brain, and reduce the adverse reactions caused by peripheral dopamine. . 3. After oral administration, 80% of levodopa degraded into dopamine metabolites within 24 hours, mainly high vanillic acid and dihydroxyphenylacetic acid, excreted by the kidneys. Some metabolites can make the urine red, and the prototype is excreted about 5%. 4. Can be secreted by milk. Read more...

Generic Name: Dexamethasone Sodium Phosphate for Injection Drug Classification: Chemical Drug Properties: Prescription Drug Related Diseases: Connective tissue disease, rheumatism, rheumatoid arthritis, lupus erythematosus, bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, Malignant lymphoma. Properties: This product is a white loose mass or powder. Main ingredients: Main ingredients: dexamethasone sodium phosphate, the auxiliary material is mannitol. Indications: Adrenal cortex hormone drugs, this product is mainly used for allergic and autoimmune inflammatory diseases. Mostly used for connective tissue disease, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colitis, acute leukemia, etc., also used in some serious infections and poisoning, malignant lymphoma Comprehensive Treatment. Specifications: 2mg. Adverse reactions: Glucocorticoids have no obvious adverse reactions in the application of physiological dose replacement therapy. Adverse reactions occur mostly in the application of pharmacological doses, and are closely related to the course of treatment, dosage, type of drug, usage and route of administration. Common adverse reactions are as follows. 1. Long-term use can cause the following side effects: iatrogenic Cushing syndrome face and body, weight gain, lower extremity edema, purple streaks, easy bleeding tendency, wound healing, hemorrhoids, menstrual disorders, hernia or avascular necrosis of the femoral head Osteoporosis and fractures (including vertebral compression fractures, long bone pathological fractures), muscle weakness, muscle atrophy, hypokalemia syndrome, gastrointestinal irritation (nausea, vomiting), pancreatitis, peptic ulcer or perforation, Child growth is inhibited, glaucoma, cataract, benign intracranial pressure rise syndrome. Dosage: 1. The general dose of this product is 2 ~ 20mg intravenously every time; intravenous drip should be diluted with 5% glucose injection, can be repeated for 2 ~ 6 hours until the condition is stable, but large doses of continuous administration No more than 72 hours. 2. For the relief of cerebral edema caused by malignant tumor, the first dose of intravenous injection of 10mg, followed by intramuscular injection of 4mg every 6 hours, generally 12 to 24 hours patients can be improved, gradually reduced after 2 to 4 days, 5 ~ 7 days to stop the drug. Contraindications: Patients with a history of allergies to this product and adrenocortical hormones are forbidden. In special cases, weigh the pros and cons, pay attention to the possibility of worsening the disease; hypertension, thrombosis, stomach and duodenal ulcer, psychosis, abnormal electrolyte metabolism, Patients with myocardial infarction, visceral surgery, glaucoma, etc. are generally not suitable for use. Note: 1. When applying to patients with tuberculosis, acute bacterial or viral infections, appropriate anti-infective treatment must be given. 2. After taking the drug for a long time, it should be gradually reduced before stopping the drug. 3. Diabetes, osteoporosis, cirrhosis, renal dysfunction, hypothyroidism patients with caution. 4. Athletes use with caution. Pregnancy and lactating women medication: Pregnancy women can increase the incidence of placental insufficiency, neonatal weight loss or stillbirth, animal testing has teratogenic effects, should be weighed against the pros and cons. If the lactating mother receives a large dose, it should not be breast-feeded to prevent the drug from being excreted through the milk, resulting in adverse reactions such as growth inhibition and inhibition of adrenal function. Pediatric Use: Children with adrenal cortex hormones should be very careful. Use hormones to inhibit the growth and development of children. If it is necessary to use them for a long time, use short-acting or intermediate-effect preparations to avoid long-acting dexamethasone preparations. And observe changes in intracranial pressure. Elderly medication: can cause adrenal hyperfunction syndrome. Drug interactions: 1. With barbiturates, phenytoin, rifampicin, the metabolism of this product is weakened. 2. In combination with salicylic acid drugs, increase its toxicity. 3. Can reduce the role of anticoagulant, oral hypoglycemic agents, should be adjusted dose. Pharmacology and Toxicology: Adrenal cortex hormone drugs. It has anti-inflammatory, anti-allergic, anti-rheumatic and immunosuppressive effects. Its mechanism of action is: 1. Anti-inflammatory effect: This product reduces and prevents tissue response to inflammation, thereby reducing the manifestations of inflammation. It inhibits the accumulation of inflammatory cells, including macrophages and leukocytes, at the site of inflammation, and inhibits phagocytosis, release of lysosomal enzymes, and synthesis and release of inflammatory chemical mediators. 2. Immunosuppressive effects: including preventing or inhibiting cell-mediated immune responses, delaying allergic reactions, reducing the number of T lymphocytes, monocytes, and acidic cells, and reducing the binding capacity of immunoglobulins to cell surface receptors. And inhibit the synthesis and release of interleukin, thereby reducing the conversion of T lymphocytes to lymphoblasts, and reducing the original immunity. Pharmacokinetics: Intramuscular injection of this product reached the peak concentration of blood in 1 hour. The plasma protein binding rate of this product is lower than other corticosteroids. Storage: Keep away from light and keep it closed. Validity period:

English name: HMG injection(Human Menopausal Gonadotrophin) Chinese name: Injectable human menopausal gonadotropin treatment category name Human pituitary gonadotropin agent General name: Human Menopausal Gonadotrophin trait White to yellow fine Powder. Slightly soluble in water. The pharmacodynamic pharmacology of FSH and LH cooperates to form a growing follicle from the primordial follicle to mature the ovarian follicle and, at the same time, promote the secretion of estrogen. Adaptation to the inter-brain (hypothalamus) amenorrhea, pituitary amenorrhea-induced ovulation usage and dosage by dissolving 75 to 150 units in the attached lysate daily follicle stimulating hormone by continuous muscle, about 300 cubic millimeters or multiple cervical mucus weight At the time of administration, the timing of the formation (crystallization) of the fern shows the third-degree investigation result as an index (4 to 20 days, usually 5 to 10 days), which switches to chorionic gonadotropin. Since the dosage and variation of the drug to be administered depends on the circumstances, it is necessary to strictly follow the use. The drug is when used with the included solution is dissolved by 1 tube 1 ml. Packing specification HMG injection: 75 * * 10 bottles (with liquid: 1 ml of normal saline 10 amps)

Common name: Compound dexamethasone acetate cream Drug classification: Chemical drug properties: Prescription drug related diseases: localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, chronic eczema. Traits: This product is a white cream; it has a specific aroma of camphor. Ingredients: This product is a compound preparation containing 0.75 mg of dexamethasone acetate per gram, 10 mg of camphor and 10 mg of menthol. Excipients are: hydroxyethyl ester, glycerin, plain plus O, cetostearyl alcohol, glyceryl monostearate, light liquid paraffin, white petrolatum, propylene glycol. Indications: For localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, and chronic eczema. Specifications: 10g Adverse reactions: Long-term use can be secondary to bacterial and fungal infections, local acne, rosacea-like dermatitis, skin atrophy and telangiectasia, and itching, pigmentation, facial erythema, wound healing disorders, etc. . Occasionally allergic reactions. Dosage: External use. 1 or 2 times a day, apply a small amount to the affected area and sneeze for a while. Contraindications: 1. The affected area has been ruptured, suppurated or obviously exuded. 2. The virus infected (if there is herpes, chickenpox) is prohibited. Note: 1. Avoid contact with eyes and other mucous membranes (such as mouth, nose, etc.). 2. Pregnant women and lactating women should be used with caution. 3. Not suitable for large-area, long-term use; symptoms are not relieved after 1 week of medication, please consult a physician. 4. If there is a burning sensation or redness in the medication site, stop the drug and wash the topical drug. If necessary, consult a physician. 5. If you have a bacterial or fungal infection, please consult your physician. 6. Athletes use with caution. 7. Children should avoid using it. 8. If you have been diagnosed with fungal infection (癣), you should not use this product alone, but you can use this product to relieve itching and anti-inflammatory while using antifungal drugs. 9. This product should not be used at the same time as other dermatological drugs. Pregnancy and lactating women medication: pregnant women, lactating women with caution. Pediatric Use: Avoid using children. Children must be under the supervision of an adult. Old man medication: The amount of maintenance is about 0.75mg (1 tablet) a day, depending on the condition. Drug interactions: 1. Non-steroidal anti-inflammatory analgesics can enhance the ulceration of glucocorticoids. 2. Drug interactions may occur if used in conjunction with other drugs. Consult your physician or pharmacist for details. Pharmacology and Toxicology: This product contains dexamethasone as a glucocorticoid with anti-inflammatory and anti-allergic effects; menthol and camphor have the effects of promoting local circulation and mild anti-inflammatory, analgesic and antipruritic effects. Pharmacokinetics: No relevant experiments were performed and no reference data were available. Storage: Sealed and kept in a cool place. Validity: 24 months.